🗞️Imugene’s Azer-Cel Shows Promise in Relapsed/Refractory Diffuse Large B-Cell Lymphoma | $IMU Media coverage by Applied Clinical Trials.

“We’re extremely encouraged by the data emerging from the Phase Ib study,” Bradley Glover, PhD, COO of Imugene $IMU, told Inside Precision Medicine. @Inside_PM

🗞️Optimizing R/R DLBCL Treatment: Azer-Cel Shows Sustained Responses | Media coverage by @TargetedOncology. $IMU #Imugene #Biotech #BiotechNews

The replay of our July 2025 Investor Webinar, featuring our Azer-cel data is now available. Executive Chairman Paul Hopper, Managing Director & CEO Leslie Chong and Chief Medical Officer Dr John Byon discuss the latest data from the azer-cel Phase 1b clinical trial in

📰 Media coverage by @Inside_PM . Take II: Off-the-Shelf CAR T Shines in Relapsed/Refractory Lymphoma Patients. Read the full article here: #IMU #ASX #ASXNews.

📰Imugene secures $22.5 million placement and launches $15 million SPP to fund azer-cel trial | Media coverage by @proactive_au . Read the full article here; $IMU #ASX #ASXNews.

We’re hosting a live webinar to present the latest data from our Phase 1b trial of azer-cel. The webinar will be hosted by Executive Chairman Paul Hopper, CEO & Managing Director Leslie Chong, and Chief Medical Officer Dr John Byon. The webinar will be held at 11am AEST on

We’ve successfully completed a strongly supported $22.5 million Placement and launched a $15 million Share Purchase Plan at $0.33 per share. Participants in the Placement and SPP will receive 3 free attaching listed options for every 4 shares subscribed, with an exercise price

Imugene Capital Raising Presentation: $IMU #Biotech #ASXnews

We've been featured on Money News. Imugene CEO & MD Leslie Chong joined the show to discuss our latest azer-cel trial results, the growing potential of allogeneic CAR T therapies, and what’s next for Imugene in the fight against blood cancer. 🎧 Listen to the full interview:

Imugene reports two additional complete responses in azer-cel CAR T Phase 1b trial | $IMU Media coverage by @AusBiotech . #AzerCel #Biotech #ImmunoOncology #CAR_T #CancerResearch #DLBCL #CellTherapy #Oncology #BloodCancer #CancerTreatment

“Two more patients are now cancer-free after failing up to six prior lines of therapy – including autologous CAR T. That’s the power of azer-cel,” – CEO & MD Leslie Chong. We’ve reported a 75% overall response rate and 55% complete response rate in our Phase 1b trial of azer-cel

Imugene's azer-cel shows strong results in Phase 1b trial for DLBCL, set for FDA meeting | $IMU Media coverage by @proactive_au.

We’ve reported two additional Complete Responses and three Partial Responses in the Phase 1b trial of azer-cel, our allogeneic off-the-shelf CD19 CAR T therapy for relapsed diffuse large B-cell #lymphoma (DLBCL). This brings the overall response rate to 75% and the Complete

“We are very pleased with the continued positive data coming from the azer-cel trial, which further reinforces its potential as a treatment for lymphoma patients who have failed on several previous therapies including auto CAR T,” CEO and managing director Leslie Chong told

Imugene receives A$5.87M R&D tax refund to support clinical programs | IMU Media coverage by @proactive_au. . #Biotech #ASXNews.

We've received our R&D tax refund for the 2024 financial year, totalling A$5,872,248, including $84,990 interest. The refund is received as part of the Australian Government’s R&D tax incentive, which provides companies engaging in appropriate and eligible activities with a

📰Imugene doses first patient in Australia for PD1-Vaxx Neo-POLEM Phase II trial | Media coverage by @proactive_au . Read the full article here; $IMU #ASX #ASXNews.